Research programme: agammaglobulinaemia-tyrosine-kinase inhibitors - Advinus Therapeutics

Drug Profile

Research programme: agammaglobulinaemia-tyrosine-kinase inhibitors - Advinus Therapeutics

Alternative Names: Bruton's tyrosine kinase inhibitors - Advinus; BTK inhibitors - Advinus Therapeutics

Latest Information Update: 02 Feb 2016

Price : $50

At a glance

  • Originator Advinus Therapeutics
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer; Inflammation

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 21 Jan 2016 BTK inhibitors - Advinus Therapeutics is available for licensing as of 21 Jan 2016. www.advinus.com
  • 21 Jan 2016 Early research in Autoimmune disorders in India (unspecified route)
  • 21 Jan 2016 Early research in Cancer in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top